ReviewFrontiers in pharmacology2025
Royal jelly acid: preparation, metabolism and therapeutic potential.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- 10-HDA Suppresses the Growth of Gastric Cancer Cells Through Inducing Apoptosis and G0/G1 Cell Cycle Arrest.Nutrients · 2026Article
- Royal jelly induces coordinated redox and energy metabolic responses in Candida guilliermondii NP-4.World journal of microbiology & biotechnology · 2026Article
- 10-Hydroxy-2-decenoic Acid Suppresses Colorectal Cancer Progression by Inhibiting Wnt/β-Catenin Signaling and Promoting Apoptosis.Foods (Basel, Switzerland) · 2026Article
- Synergistic Therapeutic Effects of Chitosan and Royal Jelly.Polymers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Royal jelly acid (10-HDA), an unsaturated fatty acid unique to royal jelly, exhibits a diverse range of biological activities, including hypoglycemic, anti-inflammatory, and anticancer properties. In recent years, the increasing demand for natural product supplements as health enhancers has led to a significant rise in the consumption of royal jelly products for daily wellness. Consequently, the market for royal jelly supplements has expanded considerably. Understanding the mechanisms underlying the biological activities of royal jelly acid is crucial for optimizing its therapeutic applications and guiding the development of innovative royal jelly-based products. This review consolidates current research on the preparation, metabolism and potential pharmacological roles of royal jelly acid in managing cancer, inflammatory disorders, and glucolipid metabolic diseases and explores the molecular mechanisms driving these effects. Future research should leverage advanced analytical techniques to uncover the intricate mechanisms of royal jelly acid's actions, paving the way for its broader integration into healthcare and clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.